Ornipressin
Also known as: 8-ornithine vasopressin, Ornipressin (M‑2), Ornipressin acetate, POR-8, Porselin, Vasopressin ornithine-8
Source Ornipressin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Ornipressin (8‑ornithine vasopressin) is a synthetic nonapeptide analogue of vasopressin approved for prescription use. It is employed as a potent vasoconstrictor in settings such as surgical hydrodissection to limit bleeding and as an adjunctive therapy for hepatorenal syndrome (HRS) in cirrhosis, usually together with albumin infusion.
Mechanism of Action
Ornipressin acts as an agonist at vasopressin V1 receptors on vascular smooth muscle, triggering phospholipase C‑mediated calcium release and marked vasoconstriction. In the splanchnic circulation this raises systemic vascular resistance and improves effective arterial blood volume, which can augment renal perfusion when combined with plasma expansion. The peptide does not appear to engage V2‑mediated antidiuretic pathways in the cited studies.
What the Research Shows
A 2016 randomised trial in 80 women undergoing vaginal prolapse surgery compared vaginal infiltration with ornipressin versus saline. Median blood loss fell from 81 ml to 35 ml (p = 0.03) without significant changes in blood pressure or pulse. Reviews of HRS management cite ornipressin plus albumin as a therapeutic option, and a 1998 uncontrolled study of 16 cirrhotic patients reported that a 15‑day course of ornipressin with albumin normalised serum creatinine, renal plasma flow and glomerular filtration rate, albeit with ischemic complications in three patients. Later reviews (2000, 2002, 2021) describe ornipressin as an adjunctive vasoconstrictor used mainly as a bridge to transplant, noting limited comparative data.
Reported Benefits
In the surgical setting, ornipressin reduces intra‑operative blood loss, potentially improving operative field visibility and decreasing transfusion needs. In HRS, short‑term administration combined with albumin can restore renal haemodynamics, lower serum creatinine, and increase glomerular filtration, offering a temporary bridge to definitive therapies such as transplant or TIPS.
Limitations of the Evidence
Evidence for surgical benefit derives from a single modest‑size RCT; larger trials are lacking. HRS data come from small, uncontrolled studies and narrative reviews, limiting conclusions about efficacy compared with other vasoconstrictors (e.g., terlipressin). The risk of ischemic complications observed with prolonged dosing restricts routine use, and ornipressin is not listed as first‑line therapy in contemporary guidelines.
Safety Considerations
The vaginal surgery trial reported no significant alterations in blood pressure or heart rate, suggesting a favourable acute cardiovascular profile when used locally. However, the 1998 HRS study noted ischemic events in three of eight patients receiving a 15‑day infusion, highlighting the potential for tissue ischemia with extended systemic exposure. As a potent vasoconstrictor, ornipressin may cause hypertension, reduced peripheral perfusion, and organ ischemia, especially at higher doses or prolonged administration.
How It Is Administered
Ornipressin is supplied for intramuscular, intravenous, sub‑cutaneous injection, and local infiltration. In surgery it is mixed with saline for hydrodissection and injected into the operative field. For HRS it is administered intravenously, often as a continuous infusion, in conjunction with albumin to expand plasma volume.
Routes of Administration
Goals & Uses
- Acute hypotension managementHemodynamic SupportModerate
- Local vasoconstriction adjunct to anesthesiaSurgical/anestheticHigh
- Control of variceal bleedingGastroenterologyModerate
- Reduction of intraoperative blood lossSurgicalModerate
- Control of intra‑operative bleedingHemostasisLow
- Management of circulatory shockCritical CareLow
Contraindications
- Hypertension (uncontrolled)CardiovascularModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe cardiovascular diseaseCardiovascularHigh
- Coronary artery diseaseCardiovascularHigh
- Hypersensitivity to ornipressin or vasopressin analoguesAllergy/ImmunologyHigh
- Peripheral vascular diseaseVascularModerate
- Severe peripheral vascular diseaseVascularHigh
Adverse Effects
- HypertensionCardiovascularCommonHigh blood pressure
- Ischemic complicationsVascularUncommon
- Nausea and vomitingGastrointestinalUncommon
- Pallor and peripheral ischemiaVascularCommon
- Tissue necrosis at injection siteLocal/DermatologicalUncommon
- Cardiac arrhythmiasCardiovascularUncommon
- BradycardiaCardiovascularCommon
Drug Interactions
- Halogenated inhalation anesthetics (e.g., halothane)High
- Beta-blockersModerate
- Tricyclic antidepressantsModerate
- Other vasoconstrictors (e.g., norepinephrine, phenylephrine)High
- NSAIDsLowMay increase renal risk in susceptible patients
- Vasodilators (e.g., nitroglycerin)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Hepatic impairment/cirrhosisOrgan ImpairmentRelative
- Elderly patientsAgeRelative
- PediatricsAgeRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization; used in experimental protocols.
- United StatesUnapprovedNot approved by FDA; available only for research.
- United KingdomUnknownLimited information on current UK regulatory status post-Brexit; historically available in some European markets.
Approved in several European countries and other jurisdictions for use as a local vasoconstrictor adjunct. Not FDA-approved in the United States. Used in clinical practice in Europe, Latin America, and parts of Asia.
Evidence & Sources
- Journal ArticleModerateHenn EW, Nondabula T, Juul L2016-01-01T00:00:00.000000Z
- Journal ArticleModerateWong F, Blendis L2000-01-01T00:00:00.000000Z
- Journal ArticleModerateBiswas KD, Jain AK2002-01-01T00:00:00.000000Z
- Journal ArticleModerateGerbes AL1993-01-01T00:00:00.000000Z
- Journal ArticleModerateOjeda-Yuren AS, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateGuevara M, et al.1998-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of drug is ornipressin?
Ornipressin is a synthetic analogue of vasopressin, classified as a nonapeptide vasopressin analogue that primarily stimulates V1 receptors to cause vasoconstriction.
How is ornipressin used during vaginal prolapse surgery?
The peptide is added to the saline used for hydrodissection, infiltrating the vaginal tissues. In a randomised trial it cut median blood loss roughly in half without affecting heart rate or blood pressure.
Can ornipressin help patients with hepatorenal syndrome?
When combined with albumin, short‑term ornipressin infusion can improve renal blood flow and lower serum creatinine, acting as a bridge to transplant or other definitive therapies, though data are from small, uncontrolled studies.
What are the main safety concerns with ornipressin?
Acute use appears well‑tolerated, but prolonged systemic infusion has been linked to ischemic complications, such as tissue hypoperfusion, and may cause hypertension or reduced peripheral blood flow.
What is Ornipressin?
Ornipressin (8‑ornithine vasopressin) is a synthetic nonapeptide analogue of vasopressin approved for prescription use. It is employed as a potent vasoconstrictor in settings such as surgical hydrodissection to limit bleeding and as an adjunctive therapy for hepatorenal syndrome (HRS) in cirrhosis, usually together with albumin infusion.
What is Ornipressin used for?
Ornipressin is educationally associated with: Acute hypotension management, Local vasoconstriction adjunct to anesthesia, Control of variceal bleeding, Reduction of intraoperative blood loss, Control of intra‑operative bleeding, Management of circulatory shock. Educational only — not medical advice.
How is Ornipressin administered?
Recorded routes of administration: Intramuscular, Intravenous, Local Infiltration, Subcutaneous, Topical.
What are the potential side effects of Ornipressin?
Reported adverse effects include: Hypertension, Ischemic complications, Nausea and vomiting, Pallor and peripheral ischemia, Tissue necrosis at injection site, Cardiac arrhythmias, Bradycardia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Ornipressin?
Recorded contraindications: Hypertension (uncontrolled), Pregnancy, Severe cardiovascular disease, Coronary artery disease, Hypersensitivity to ornipressin or vasopressin analogues, Peripheral vascular disease, Severe peripheral vascular disease. Consult a qualified clinician before use.